세계의 지속성 상피결손 관리 시장 보고서(2025년)

Persistent Epithelial Defect (PED) Management encompasses medical strategies aimed at promoting corneal healing when the corneal epithelium fails to regenerate and close within two weeks despite standard treatment. This approach involves identifying and addressing underlying causes while utilizing therapeutic methods such as lubricating eye drops, autologous serum tears, amniotic membrane transplantation, bandage contact lenses, and biologic therapies. These interventions help facilitate epithelial healing and prevent complications such as corneal ulcers or perforation.

The primary disease categories in persistent epithelial defect management include epithelial or limbal conditions, inflammatory diseases, neurotrophic diseases, and other related conditions. Epithelial and limbal disorders impact the corneal epithelium and limbal stem cells, resulting in vision-threatening defects due to impaired corneal regeneration. Medications are distributed through various channels, including direct sales, online pharmacies, retail pharmacies, and hospitals. These drugs serve different end users, such as hospital or clinical laboratories, physician offices, reference laboratories, and other medical institutions.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The persistent epithelial defect management market research report is one of a series of new reports from The Business Research Company that provides persistent epithelial defect management market statistics, including the persistent epithelial defect management industry global market size, regional shares, competitors with the persistent epithelial defect management market share, detailed persistent epithelial defect management market segments, market trends, and opportunities, and any further data you may need to thrive in the persistent epithelial defect management industry. This persistent epithelial defect management market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The persistent epithelial defect management market size has grown rapidly in recent years. It will grow from $7.92 billion in 2024 to $9.26 billion in 2025 at a compound annual growth rate (CAGR) of 17.0%. The growth in the historic period can be attributed to increased research activities, higher demand for hospitals, increasing prevalence of ocular surface disorders, increasing prevalence of eye disorders, aging population.

The persistent epithelial defect management market size is expected to see rapid growth in the next few years. It will grow to $17.17 billion in 2029 at a compound annual growth rate (CAGR) of 16.7%. The growth in the forecast period can be attributed to increased partnerships and collaborations, growing awareness and education, focus on value based care, rising prevalence of conditions like diabetes and hypertension, early intervention and management. Major trends in the forecast period include technological advancements, increasing demand of innovative treatment types, advanced treatment modalities, availability of advanced surgical tools and techniques, innovative drugs.

The forecast of 16.7% growth over the next five years reflects a modest reduction of 0.2% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may disrupt U.S. ophthalmology practices by increasing costs for amniotic membrane grafts and bandage contact lenses imported from Greece and Ireland, potentially prolonging corneal healing times and raising clinic operational expenses. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The growing prevalence of eye disorders is anticipated to drive the expansion of the persistent epithelial defect management market. Eye disorders encompass a wide range of medical conditions that impact the structure, function, or overall health of the eyes, leading to vision impairment, discomfort, or potential blindness. Factors such as aging populations, prolonged screen exposure, and environmental changes contribute to the rising prevalence of these conditions. Effective management of persistent epithelial defects is crucial for treating eye disorders, as it facilitates healing, reduces inflammation, and prevents complications such as infection or scarring. For example, in December 2024, the World Health Organization, a Switzerland-based intergovernmental organization, reported that the overall pooled prevalence of childhood myopia was 5.23% in 2023, with a notably higher rate among females (4.90%) compared to males (3.94%). As a result, the increasing occurrence of eye disorders is fueling the growth of the persistent epithelial defect management market.

The growing number of eye surgeries is also expected to boost the persistent epithelial defect management market. Eye surgeries involve medical procedures performed to correct vision problems, treat diseases, or repair injuries. This increase in surgical procedures is driven by the rising prevalence of eye disorders such as cataracts, glaucoma, and refractive errors, alongside advancements in surgical techniques and the widespread adoption of minimally invasive procedures. Effective persistent epithelial defect management plays a vital role in eye surgeries by promoting corneal healing, reducing complications, and enhancing visual outcomes through targeted treatments that support epithelial regeneration. For instance, in 2023, the Eye Bank Association of America, a US-based transplant association, reported a 2.7% increase in domestic keratoplasty procedures, rising from 49,597 in 2022 to 50,925 in 2023. This growing trend in eye surgeries is contributing to the expansion of the persistent epithelial defect management market.

Leading companies in the persistent epithelial defect management market are focusing on innovative treatments such as secretome therapy to accelerate healing and enhance treatment outcomes. Secretome therapy involves using bioactive molecules secreted by cells, including proteins, lipids, and extracellular vesicles, to promote tissue repair, modulate immune responses, and treat various diseases. For example, in April 2023, Kala Pharmaceuticals Inc., a US-based biopharmaceutical company, received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for KPI-012, a human MSC-S therapy designed for persistent corneal epithelial defects. This therapy employs a multifactorial mechanism of action to address all underlying causes of persistent epithelial defects by facilitating corneal healing through bioactive molecules such as growth factors, protease inhibitors, and neurotrophic factors.

Major players in the persistent epithelial defect management market are AbbVie Inc., Novartis AG, Johnson & Johnson Vision, RegeneRx Biopharmaceuticals Inc., Regeneron Pharmaceuticals Inc., Alcon Inc., Bausch Health Companies Inc., Hoya Vision Care, Santen Pharmaceutical Co. Ltd., Recordati Rare Diseases Inc., Dompe Farmaceutici S.p.A., Lumenis Ltd., TissueTech Inc., Ocular Therapeutix Inc., Oculus Surgical Inc., Amber Ophthalmics Inc., Noveome Biotherapeutics Inc., OcuNexus Therapeutics Inc., Lux Bio Inc., Eyenovia Inc.

North America was the largest region in the persistent epithelial defect management market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in persistent epithelial defect management report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the persistent epithelial defect management market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The persistent epithelial defect management market consists of revenues earned by entities by providing services such as pharmacological treatments, amniotic membrane transplantation, bandage contact lenses, and tarsorrhaphy procedures. The market value includes the value of related goods sold by the service provider or included within the service offering. The persistent epithelial defect management market also includes sales of autologous serum eye drops, regenerative biologic eye drops, bandage contact lenses, and amniotic membrane grafts. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Persistent Epithelial Defect Management Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on persistent epithelial defect management market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for persistent epithelial defect management ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The persistent epithelial defect management market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Disease Type: Epithalial Or Limbal; Inflammatory Disease; Neurotrophic Disease; Other Disease Types
• 2) By Distribution Channel: Direct Sales; Online Pharmacy; Retail Pharmacy; Hospitals
• 3) By End User: Hospital Or Clinical Laboratories; Physician Offices; Reference Laboratories; Other End Users
• Subsegments:
• 1) By Epithelial Or Limbal: Limbal Stem Cell Deficiency (LSCD); Limbal Transplantation; Conjunctival Transplantation
• 2) By Inflammatory Disease: Dry Eye Syndrome; Allergic Conjunctivitis; Uveitis
• 3) By Neurotrophic Disease: Herpes Simplex Virus (HSV) Keratitis; Diabetic Neuropathy; Neurotrophic Keratopathy
• 4) By Other Disease Types: Chemical Burns; Trauma-Induced Defects; Congenital Corneal Opacities
• Companies Mentioned: AbbVie Inc.; Novartis AG; Johnson & Johnson Vision; RegeneRx Biopharmaceuticals Inc.; Regeneron Pharmaceuticals Inc.; Alcon Inc.; Bausch Health Companies Inc.; Hoya Vision Care; Santen Pharmaceutical Co. Ltd.; Recordati Rare Diseases Inc.; Dompe Farmaceutici S.p.A.; Lumenis Ltd.; TissueTech Inc.; Ocular Therapeutix Inc.; Oculus Surgical Inc.; Amber Ophthalmics Inc.; Noveome Biotherapeutics Inc.; OcuNexus Therapeutics Inc.; Lux Bio Inc.; Eyenovia Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Persistent Epithelial Defect Management Market Characteristics

3. Persistent Epithelial Defect Management Market Trends And Strategies

4. Persistent Epithelial Defect Management Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Persistent Epithelial Defect Management Growth Analysis And Strategic Analysis Framework

• 5.1. Global Persistent Epithelial Defect Management PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Persistent Epithelial Defect Management Market Growth Rate Analysis
• 5.4. Global Persistent Epithelial Defect Management Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Persistent Epithelial Defect Management Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Persistent Epithelial Defect Management Total Addressable Market (TAM)

6. Persistent Epithelial Defect Management Market Segmentation

• 6.1. Global Persistent Epithelial Defect Management Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Epithalial Or Limbal
• Inflammatory Disease
• Neurotrophic Disease
• Other Disease Types
• 6.2. Global Persistent Epithelial Defect Management Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Direct Sales
• Online Pharmacy
• Retail Pharmacy
• Hospitals
• 6.3. Global Persistent Epithelial Defect Management Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Or Clinical Laboratories
• Physician Offices
• Reference Laboratories
• Other End Users
• 6.4. Global Persistent Epithelial Defect Management Market, Sub-Segmentation Of Epithelial Or Limbal, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Limbal Stem Cell Deficiency (LSCD)
• Limbal Transplantation
• Conjunctival Transplantation
• 6.5. Global Persistent Epithelial Defect Management Market, Sub-Segmentation Of Inflammatory Disease, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Dry Eye Syndrome
• Allergic Conjunctivitis
• Uveitis
• 6.6. Global Persistent Epithelial Defect Management Market, Sub-Segmentation Of Neurotrophic Disease, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Herpes Simplex Virus (HSV) Keratitis
• Diabetic Neuropathy
• Neurotrophic Keratopathy
• 6.7. Global Persistent Epithelial Defect Management Market, Sub-Segmentation Of Other Disease Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemical Burns
• Trauma-Induced Defects
• Congenital Corneal Opacities

7. Persistent Epithelial Defect Management Market Regional And Country Analysis

• 7.1. Global Persistent Epithelial Defect Management Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Persistent Epithelial Defect Management Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Persistent Epithelial Defect Management Market

• 8.1. Asia-Pacific Persistent Epithelial Defect Management Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Persistent Epithelial Defect Management Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Persistent Epithelial Defect Management Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Persistent Epithelial Defect Management Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Persistent Epithelial Defect Management Market

• 9.1. China Persistent Epithelial Defect Management Market Overview
• 9.2. China Persistent Epithelial Defect Management Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Persistent Epithelial Defect Management Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Persistent Epithelial Defect Management Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Persistent Epithelial Defect Management Market

• 10.1. India Persistent Epithelial Defect Management Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Persistent Epithelial Defect Management Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Persistent Epithelial Defect Management Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Persistent Epithelial Defect Management Market

• 11.1. Japan Persistent Epithelial Defect Management Market Overview
• 11.2. Japan Persistent Epithelial Defect Management Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Persistent Epithelial Defect Management Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Persistent Epithelial Defect Management Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Persistent Epithelial Defect Management Market

• 12.1. Australia Persistent Epithelial Defect Management Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Persistent Epithelial Defect Management Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Persistent Epithelial Defect Management Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Persistent Epithelial Defect Management Market

• 13.1. Indonesia Persistent Epithelial Defect Management Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Persistent Epithelial Defect Management Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Persistent Epithelial Defect Management Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Persistent Epithelial Defect Management Market

• 14.1. South Korea Persistent Epithelial Defect Management Market Overview
• 14.2. South Korea Persistent Epithelial Defect Management Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Persistent Epithelial Defect Management Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Persistent Epithelial Defect Management Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Persistent Epithelial Defect Management Market

• 15.1. Western Europe Persistent Epithelial Defect Management Market Overview
• 15.2. Western Europe Persistent Epithelial Defect Management Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Persistent Epithelial Defect Management Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Persistent Epithelial Defect Management Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Persistent Epithelial Defect Management Market

• 16.1. UK Persistent Epithelial Defect Management Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Persistent Epithelial Defect Management Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Persistent Epithelial Defect Management Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Persistent Epithelial Defect Management Market

• 17.1. Germany Persistent Epithelial Defect Management Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Persistent Epithelial Defect Management Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Persistent Epithelial Defect Management Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Persistent Epithelial Defect Management Market

• 18.1. France Persistent Epithelial Defect Management Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Persistent Epithelial Defect Management Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Persistent Epithelial Defect Management Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Persistent Epithelial Defect Management Market

• 19.1. Italy Persistent Epithelial Defect Management Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Persistent Epithelial Defect Management Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Persistent Epithelial Defect Management Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Persistent Epithelial Defect Management Market

• 20.1. Spain Persistent Epithelial Defect Management Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Persistent Epithelial Defect Management Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Persistent Epithelial Defect Management Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Persistent Epithelial Defect Management Market

• 21.1. Eastern Europe Persistent Epithelial Defect Management Market Overview
• 21.2. Eastern Europe Persistent Epithelial Defect Management Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Persistent Epithelial Defect Management Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Persistent Epithelial Defect Management Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Persistent Epithelial Defect Management Market

• 22.1. Russia Persistent Epithelial Defect Management Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Persistent Epithelial Defect Management Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Persistent Epithelial Defect Management Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Persistent Epithelial Defect Management Market

• 23.1. North America Persistent Epithelial Defect Management Market Overview
• 23.2. North America Persistent Epithelial Defect Management Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Persistent Epithelial Defect Management Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Persistent Epithelial Defect Management Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Persistent Epithelial Defect Management Market

• 24.1. USA Persistent Epithelial Defect Management Market Overview
• 24.2. USA Persistent Epithelial Defect Management Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Persistent Epithelial Defect Management Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Persistent Epithelial Defect Management Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Persistent Epithelial Defect Management Market

• 25.1. Canada Persistent Epithelial Defect Management Market Overview
• 25.2. Canada Persistent Epithelial Defect Management Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Persistent Epithelial Defect Management Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Persistent Epithelial Defect Management Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Persistent Epithelial Defect Management Market

• 26.1. South America Persistent Epithelial Defect Management Market Overview
• 26.2. South America Persistent Epithelial Defect Management Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Persistent Epithelial Defect Management Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Persistent Epithelial Defect Management Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Persistent Epithelial Defect Management Market

• 27.1. Brazil Persistent Epithelial Defect Management Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Persistent Epithelial Defect Management Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Persistent Epithelial Defect Management Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Persistent Epithelial Defect Management Market

• 28.1. Middle East Persistent Epithelial Defect Management Market Overview
• 28.2. Middle East Persistent Epithelial Defect Management Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Persistent Epithelial Defect Management Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Persistent Epithelial Defect Management Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Persistent Epithelial Defect Management Market

• 29.1. Africa Persistent Epithelial Defect Management Market Overview
• 29.2. Africa Persistent Epithelial Defect Management Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Persistent Epithelial Defect Management Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Persistent Epithelial Defect Management Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Persistent Epithelial Defect Management Market Competitive Landscape And Company Profiles

• 30.1. Persistent Epithelial Defect Management Market Competitive Landscape
• 30.2. Persistent Epithelial Defect Management Market Company Profiles
  • 30.2.1. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Johnson & Johnson Vision Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. RegeneRx Biopharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Regeneron Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Persistent Epithelial Defect Management Market Other Major And Innovative Companies

• 31.1. Alcon Inc.
• 31.2. Bausch Health Companies Inc.
• 31.3. Hoya Vision Care
• 31.4. Santen Pharmaceutical Co. Ltd.
• 31.5. Recordati Rare Diseases Inc.
• 31.6. Dompe Farmaceutici S.p.A.
• 31.7. Lumenis Ltd.
• 31.8. TissueTech Inc.
• 31.9. Ocular Therapeutix Inc.
• 31.10. Oculus Surgical Inc.
• 31.11. Amber Ophthalmics Inc.
• 31.12. Noveome Biotherapeutics Inc.
• 31.13. OcuNexus Therapeutics Inc.
• 31.14. Lux Bio Inc.
• 31.15. Eyenovia Inc.

32. Global Persistent Epithelial Defect Management Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Persistent Epithelial Defect Management Market

34. Recent Developments In The Persistent Epithelial Defect Management Market

35. Persistent Epithelial Defect Management Market High Potential Countries, Segments and Strategies

• 35.1 Persistent Epithelial Defect Management Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Persistent Epithelial Defect Management Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Persistent Epithelial Defect Management Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer